BIOGEN INC

Biogen’s Form 3 filing shows a lone share purchased by its chief legal officer, hinting at potential future moves despite no market impact.

Biogen’s analyst upgrades, strong pipeline, and market‑access focus signal solid growth prospects amid upcoming patent cliffs, boosting investor confidence.

Biogen’s Q2 2026 results show modest revenue growth and a new earnings outlook, driven by Apellis acquisitions and strong Leqembi sales, hinting at a diversified future.

Biogen’s subcutaneous lecanemab boosts early Alzheimer’s access, cuts costs by 10‑15 %, and adds 4‑year patent protection—powering stronger revenue and a strategic moat.

Biogen (BIIB) shares rise as healthcare outpaces tech, fueled by confidence in its rare‑disease pipeline and strategic portfolio expansion.

Biogen Inc.’s decade‑long stock swings reveal biotech’s volatile mix of R&D, pricing pressure and supply‑chain risk—insights for investors, clinicians and policy makers.

Biogen’s hidden strengths emerge from mRNA, digital‑therapeutics, and a solid pipeline, but patent cliffs and pricing pressure threaten its 2025 growth targets.

Biogen’s CEO buys 1,342 shares, plus a 3‑year RSU, showing exec confidence and aligning long‑term incentives with shareholder value.

Biogen’s $5.6 billion purchase of Apellis adds approved drugs Syfovre and Empaveli, expanding its rare disease and immunology portfolio with proven efficacy and a strong growth outlook.

Biogen’s litifilimab shows significant Phase‑2 success in cutaneous lupus, offering a targeted IFN‑α blocker that could reshape autoimmune therapy.